SOLIGENIX, INC.

Profile

Company Names

SOLIGENIX, INC.
DOR BIOPHARMA INC

Addresses

29 EMMONS DRIVE, SUITE C-10, PRINCETON, NJ 08540

850 BEAR TAVERN ROAD, SUITE 201, EWING, NJ 08628

Phone Numbers

609-538-8200

 

Entity Type:

CORPORATION

Industry:

PHARMACEUTICALS, BIOTECHNOLOGY

Year Incorporated:

> 5 years ago

State Incorporated:

DE

Total Amount Raised:

$16,552,477.00

Number of Funding Rounds:

6
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
6
2017-11-02 
$1,964,000.00 
$1,964,000.00 
$0.00 
Equity 
5
2013-04-27 
$1,500,000.00 
$1,500,000.00 
$0.00 
Equity 
4
2010-06-18 
$5,904,277.00 
$5,904,277.00 
$0.00 
Equity 
3
2009-03-06 
$300,000.00 
$400,000.00 
$100,000.00 
Equity 
2
2009-02-11 
$4,500,000.00 
$4,500,000.00 
$0.00 
Equity 
1
2009-01-20 
$2,384,200.00 
$2,384,200.00 
$0.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
ROBERT 
BREY 
EXECUTIVE OFFICER
ROBERT 
N. 
BREY, PH.D. 
EXECUTIVE OFFICER
KEITH 
L. 
BROWNLIE, C.P.A. 
DIRECTOR
KEITH 
L. 
BROWNLIE, CPA 
DIRECTOR
MARCO 
M. 
BRUGHERA, DVM 
DIRECTOR
CYRILLE 
 
BUHRMAN 
DIRECTOR
CYRILLE 
BUHRMAN 
DIRECTOR
CYRILLE 
F. 
BUHRMAN 
DIRECTOR
R. 
CHRISTOPHER 
CAVALLI, PHD 
EXECUTIVE OFFICER
JAMES 
 
CLAVIJO 
EXECUTIVE OFFICER
OREOLA 
 
DONINI, PHD 
EXECUTIVE OFFICER
BRIAN 
 
HAMILTON 
EXECUTIVE OFFICER
BRIAN 
L. 
HAMILTON, M.D., PH.D. 
EXECUTIVE OFFICER
KEVIN 
J. 
HORGAN, M.D. 
EXECUTIVE OFFICER
KAREN 
 
KRUMEICH 
EXECUTIVE OFFICER
JAMES 
KUO 
DIRECTOR
GREG 
LAPOINTE 
DIRECTOR
GREGG 
A. 
LAPOINTE, C.P.A. 
DIRECTOR
GREGG 
A. 
LAPOINTE, C.P.A., M.B.A. 
DIRECTOR
GREGG 
A. 
LAPOINTE, CPA 
DIRECTOR
EVAN 
 
MYRAINTHOPOULOS 
EXECUTIVE OFFICER, DIRECTOR
EVAN 
 
MYRIANTHOPOULOS 
EXECUTIVE OFFICER, DIRECTOR
ROBERT 
J. 
RUBIN, M.D. 
DIRECTOR
ROBERT 
J. 
RUBIN, MD 
DIRECTOR
ADAM 
T. 
RUMAGE 
EXECUTIVE OFFICER
CHRISTOPHER 
SCHABER 
EXECUTIVE OFFICER, DIRECTOR
CHRISTOPHER 
J. 
SCHABER, PH.D. 
EXECUTIVE OFFICER, DIRECTOR
CHRISTOPHER 
J. 
SCHABER, PHD 
EXECUTIVE OFFICER, DIRECTOR
CHRISTOPHER 
P. 
SCHNITTKER, C.P.A. 
EXECUTIVE OFFICER
RICHARD 
C. 
STRAUBE, MD MSC 
EXECUTIVE OFFICER
JOSEPH 
M. 
WARUSZ, C.P.A. 
EXECUTIVE OFFICER
JEROME 
B. 
ZELDIS, M.D., PH.D. 
DIRECTOR
JEROME 
B. 
ZELDIS, PHD 
DIRECTOR
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
D
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2017-11-02 
D
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
$1,000,001 - $5,000,000 
Equity 
2013-04-27 
D
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
$1,000,001 - $5,000,000 
Equity 
2010-06-18 
D
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
$1,000,001 - $5,000,000 
Equity 
2009-03-06 
D
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
$1,000,001 - $5,000,000 
Equity 
2009-02-11 
D
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
$1,000,001 - $5,000,000 
Equity 
2009-01-20 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
NONE
NONE
AEGIS CAPITAL CORP.
BRIAN A. FRIEDMAN
NATIONAL SECURITIES CORPORATION
ADRIAN STECYK
GRIFFIN SECURITIES, INC.